{
    "organizations": [],
    "uuid": "460f1c433b3872fb71d7e02e3ae25b3ec94cde99",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kiadis-pharma-annoucnes-consistent/brief-kiadis-pharma-annoucnes-consistent-results-from-single-dose-1-year-with-prior-phase-ii-study-idUSFWN1PP1GQ",
    "ord_in_thread": 0,
    "title": "BRIEF-Kiadis Pharma Annoucnes Consistent Results From Single Dose 1-year With Prior Phase II Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 31 (Reuters) - KIADIS PHARMA NV:\n* KIADIS PHARMA NV - LAST PATIENT DOSED WITH ATIR101™ IN PHASE II ‘008’ CLINICAL TRIAL\n* KIADIS PHARMA NV - RESULTS FROM SINGLE DOSE 1-YEAR FOLLOW UP CONSISTENT WITH PRIOR PHASE II STUDY\n* KIADIS PHARMA NV - DATA SUPPORTS ALREADY SUBMITTED MARKETING AUTHORIZATION APPLICATION\n* KIADIS PHARMA NV - REMAINS ON TRACK TO POTENTIALLY OBTAIN (CONDITIONAL) EMA APPROVAL FOR ATIR101™ IN Q4 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-31T15:24:00.000+02:00",
    "crawled": "2018-02-01T15:30:40.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "kiadis",
        "pharma",
        "nv",
        "kiadis",
        "pharma",
        "nv",
        "last",
        "patient",
        "dosed",
        "phase",
        "ii",
        "clinical",
        "trial",
        "kiadis",
        "pharma",
        "nv",
        "result",
        "single",
        "dose",
        "follow",
        "consistent",
        "prior",
        "phase",
        "ii",
        "study",
        "kiadis",
        "pharma",
        "nv",
        "data",
        "support",
        "already",
        "submitted",
        "marketing",
        "authorization",
        "application",
        "kiadis",
        "pharma",
        "nv",
        "remains",
        "track",
        "potentially",
        "obtain",
        "conditional",
        "ema",
        "approval",
        "q4",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}